Ventricular Assist Devices Market Poised for Heightened Growth in Healthcare Sector Along with Eminent Players by 2026



Ventricular assist devices are external devices attached to a patient’s body, which helps to pump blood to whole body. It is principally used in case of patients with heart failure. It is a high-end device that mimics the function of the heart. Heart failure is a condition in which heart muscles weaken, and thus unable to pump sufficient amount of blood to body. Various conditions such as heart attacks, high blood pressure, defective heart valves, irregular heart rhythms, diabetes, and chronic kidney and lung diseases cause heart failure.

Medication, implantable heart devices (pacemakers), and heart transplantation are some of the options for treatment of heart failure. However, these approaches have limitations that may lead to advanced heart failure condition, thereby increasing the demand for ventricular assist devices (VADs). VADs lowers the work load on failing heart and help in maintaining smooth blood flow to vital organs. These devices were originally designed to temporarily assist surgeons while performing transplant surgeries or while treating other medical problems. However, VADs eventually emerged as a pioneer life support for patients suffering from the final stage of heart failure. VADs consist of three parts namely, inflow pipe that receives blood from ventricles, pump that pulls blood from ventricles and pushes it into outflow pipe that carries blood to aorta to supply blood to body.

Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1686

Regional Insights:

Ventricular assist devices market is geographically divided into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The market in North America is expected to hold a dominant position in the VADs market during forecasted period due to high prevalence of heart failure and affordability of these devices in the region. According to a study published in the Journal Circulation in 2016, over 5.7 million people in the U.S. suffered suffering from HF (heart failure), which is expected to increase to 8 million by 2030 and over 250,000 patients are expected to develop advanced heart failure, thus requiring VADs. Shortage of heart donors in the U.S. is also expected to drive growth of the market.

According to statistics provided by the American College of Cardiology in 2017, only 2,200 heart donor are available each year in the U.S. Europe is a lucrative region for ventricular assist devices market, as it accounts for the highest geriatric population in world according UN report in 2017 (25% of entire population) along with high prevalence of heart failure. According to report by the European Heart Network, in 2017, cardiovascular diseases cause 3.9 million deaths in Europe and over 1.8 million deaths in the European Union, each year. Asia Pacific is expected to represent enormous opportunities for market growth in the near future, owing to the growing mortality rate caused due to CVD in the region. More than 75% deaths occurs in middle-low income countries 2as per WHO factsheet 2016)

Competitive Landscape:

Key players operating in the ventricular assist devices market include Abiomed, Inc., Abbott Laboratories, Heart Ware International, Inc, Berlin Heart GmbH, Thoratec, Inc., Liva Nova plc, Jarvik Heart, Inc., Medtronic plc, ReliantHeart, Inc., and Calon Cardio-Technology Ltd.

Market Taxonomy:

On the basis of application, ventricular assist devices market is segmented into
• Bridge to Recovery Post-surgery
• Transplantation Bridge
• Destination/Life Support

On the basis of product type, ventricular assist devices market is segmented into
• Left Ventricular Assist Devices
• Right Ventricular Assist Devices

On the basis of design, ventricular assist devices market is segmented into
• Implantable Ventricular Assist Devices
• Transcutaneous Ventricular Assist Devices

On the basis of region, ventricular assist devices market is segmented into
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Comments

Post a Comment

Popular posts from this blog

Why the Cold Pain Therapy is a Growing Payer Opportunity?

Image
Cold pain therapy is a therapeutic application of cold, used in the treatment of acute soft tissue injuries and to reduce the pain in post-operative condition in orthopedic surgeries, treatment of benign and malignant lesions, and in pain management. Cryotherapy can be applied topically (on the skin surface), surgically or percutaneously. This can also be used to treat various skin conditions such as oral mucositis and tumors in the liver, kidney, bones, breasts and lungs, skin tumors, skin tags, pre-cancerous skin moles, and injuries. Cryosurgery procedure involves use of extreme cold, produced with help of liquid nitrogen (or argon gas) to destroy abnormal tissues. According to the National Cancer Institute (NCI), cryosurgery is used for treatment of several types of cancers and some non-cancerous conditions. It is reported to be effective for treatment in early stage skin cancer, retinoblastoma, actinic keratosis, and cervical intraepithelial neoplasia. Accord...
Read more

Ursodeoxycholic Acid Market Shows Boosted Growth Rate 2018-2026 Estimated by Global Top Players

Image
Ursodeoxycholic acid (UDCA) is a bile acid taken as either a tablet or liquid to treat gallstones and to treat and prevent the progression of cystic fibrosis-related liver disorder. UDCA modifies the bile acid pool by decreasing levels of hydrophobic bile acids while increasing proportion of nontoxic hydrophilic bile acids. UDCA can delay development of gastroesophageal varices and progression to cirrhosis. Moreover it can improve long-term survival in patients with primary biliary cirrhosis. Significant improvement in liver health can be achieved during UDCA therapy in patients with intrahepatic cholestasis of pregnancy, primary sclerosing cholangitis, nonalcoholic fatty liver disease, cystic fibrosis-associated liver disease, total parenteral nutrition-induced cholestasis, graft related liver disease, and in some pediatric cholestatic liver diseases. The global ursodeoxycholic acid market size was valued at US$ 346.2 million in 2017, and is expected to witn...
Read more

Booms and Busts in Anatomic Pathology Market; Dynamics Trends Over The Time Discussed 2018-2026

Image
Anatomic pathology involves direct visualization of human tissue as gross examination as well as under a microscope for proper diagnosis of the disease or a pathological condition. Subtypes of anatomic pathology include surgical pathology, oral and maxillofacial pathology, cytopathology, molecular pathology, and forensic pathology. Procedures performed in anatomic pathology include gross examination, histopathology, immunohistochemistry, in situ hybridization, cryopathology, tissue cytogenetics, and others. Standard approach in anatomical pathology is microscopic examination of tissue samples with the help of one or more stains. Manufacturers have developed stains to identify and classify microorganisms in biopsy of tissue samples or excisional specimens. Various gram stains and acid-fast stains have applications in detection of bacteria and mycobacteria in tissue samples. Commercially available products include tissue processing systems, microtomes, cryostats, ...
Read more